Cellectis (NASDAQ:CLLS - Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03), Zacks reports. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $12.03 million for the quarter, compared to analyst estimates of $12.71 million.
Cellectis Price Performance
NASDAQ CLLS traded up $0.12 during mid-day trading on Friday, hitting $1.58. The stock had a trading volume of 49,716 shares, compared to its average volume of 142,810. Cellectis has a 52-week low of $1.10 and a 52-week high of $3.00. The company has a market cap of $87.82 million, a price-to-earnings ratio of -1.22 and a beta of 3.11. The company has a 50 day simple moving average of $1.39 and a 200 day simple moving average of $1.58. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.
Analysts Set New Price Targets
CLLS has been the subject of a number of analyst reports. Barclays cut their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Tuesday. StockNews.com downgraded Cellectis from a "buy" rating to a "hold" rating in a research note on Monday, May 12th.
Check Out Our Latest Stock Analysis on Cellectis
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
